ES2446306T3 - Uso de un inhibidor de psd-95 tratamiento para la epilepsia - Google Patents

Uso de un inhibidor de psd-95 tratamiento para la epilepsia Download PDF

Info

Publication number
ES2446306T3
ES2446306T3 ES09747499.3T ES09747499T ES2446306T3 ES 2446306 T3 ES2446306 T3 ES 2446306T3 ES 09747499 T ES09747499 T ES 09747499T ES 2446306 T3 ES2446306 T3 ES 2446306T3
Authority
ES
Spain
Prior art keywords
epilepsy
inhibitor
peptide
episode
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09747499.3T
Other languages
English (en)
Spanish (es)
Inventor
James Gurd
Crystal Dykstra
Michael Tymianski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Application granted granted Critical
Publication of ES2446306T3 publication Critical patent/ES2446306T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES09747499.3T 2008-05-16 2009-05-13 Uso de un inhibidor de psd-95 tratamiento para la epilepsia Active ES2446306T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5410908P 2008-05-16 2008-05-16
US54109P 2008-05-16
PCT/US2009/043831 WO2009140416A2 (en) 2008-05-16 2009-05-13 Treatment for epilepsy

Publications (1)

Publication Number Publication Date
ES2446306T3 true ES2446306T3 (es) 2014-03-07

Family

ID=41319319

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09747499.3T Active ES2446306T3 (es) 2008-05-16 2009-05-13 Uso de un inhibidor de psd-95 tratamiento para la epilepsia

Country Status (9)

Country Link
US (1) US9161965B2 (enExample)
EP (1) EP2307035B1 (enExample)
JP (2) JP6005357B2 (enExample)
CN (1) CN102088990A (enExample)
AU (1) AU2009246316B2 (enExample)
CA (1) CA2724483C (enExample)
DK (1) DK2307035T3 (enExample)
ES (1) ES2446306T3 (enExample)
WO (1) WO2009140416A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
JP6005357B2 (ja) 2008-05-16 2016-10-12 ノノ インコーポレイテッド てんかんの治療
AU2009288088B2 (en) * 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain
US20140323924A1 (en) * 2013-04-26 2014-10-30 David J. Mishelevich Targeted optogenetic neuromodulation for treatment of clinical conditions
CN105072993B (zh) 2013-01-31 2020-04-14 加利福尼亚大学董事会 正常和疾病状态脑动力学的建模系统和方法
JP6884703B2 (ja) 2015-02-25 2021-06-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 障害を治療するための５ｈｔ作動薬
WO2017093354A1 (en) 2015-11-30 2017-06-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Nmdar antagonists for the treatment of diseases associated with angiogenesis
ES2869300T3 (es) * 2016-04-27 2021-10-25 Biocells Beijing Biotech Co Ltd Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
KR20180135493A (ko) * 2016-04-27 2018-12-20 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상의 치료 방법
KR102871666B1 (ko) 2016-12-09 2025-10-15 알렉스자 파마스티칼즈, 인크. 간질 치료 방법
EA039314B1 (ru) * 2017-07-05 2022-01-12 Биоселз (Бейдзин) Биотек Ко., Лтд. Фармацевтически приемлемые соли полипептидов и их применение
WO2019061395A1 (zh) 2017-09-30 2019-04-04 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗肽组合物
CA3085576A1 (en) 2017-12-13 2019-06-20 The Research Foundation For The State University Of New York Peptides and other agents for treating pain and increasing pain sensitivity
EP3746138B1 (en) 2018-02-02 2025-12-10 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device
CN113164527A (zh) * 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
EP4031114A1 (en) * 2019-09-17 2022-07-27 Zogenix International Limited Methods of treating epileptic patients with fenfluramine
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
CN111285923B (zh) * 2020-03-05 2023-02-03 成都奥达生物科技有限公司 一种psd-95抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US20050019841A1 (en) * 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
US20050282743A1 (en) * 2001-08-03 2005-12-22 Arbor Vita Corporation Molecular interactions in cells
US20090075377A1 (en) * 2001-08-03 2009-03-19 Arbor Vita Corporation Molecular interactions in cells
US7858322B2 (en) * 2003-12-23 2010-12-28 Nono, Inc. Method of determining inhibition of binding to TRPM7 protein
WO2005097090A2 (en) * 2004-04-05 2005-10-20 Icos Corporation AGENTS THAT DISRUPT PSD95 - nNOS INTERACTION, COMPOSITIONS CONTAINING THE SAME, AND THERAPEUTIC USES THEREOF
WO2007002395A1 (en) * 2005-06-23 2007-01-04 Arbor Vita Corporation Methods and compositions for modulating cox
US20070021501A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods of treating epileptogenesis
US8633160B2 (en) * 2005-12-30 2014-01-21 Nono Inc. Small molecule inhibitors of PDZ interactions
KR101384572B1 (ko) * 2005-12-30 2014-04-24 아버 비타 코포레이션 Ｐｄｚ 상호작용의 소형 분자 억제제
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
EP2120987B1 (en) * 2007-03-02 2014-01-15 NoNO Inc. Treating stroke and other diseases without inhibiting n-type calcium channels
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
JP6005357B2 (ja) 2008-05-16 2016-10-12 ノノ インコーポレイテッド てんかんの治療
AU2009288088B2 (en) * 2008-09-03 2014-12-04 Nono Inc. Agents and methods for treatment of pain

Also Published As

Publication number Publication date
JP2011520900A (ja) 2011-07-21
EP2307035B1 (en) 2013-12-04
CA2724483A1 (en) 2009-11-19
WO2009140416A3 (en) 2010-01-14
US20100160240A1 (en) 2010-06-24
JP6005357B2 (ja) 2016-10-12
EP2307035A4 (en) 2012-04-11
AU2009246316A1 (en) 2009-11-19
CA2724483C (en) 2018-01-02
CN102088990A (zh) 2011-06-08
DK2307035T3 (da) 2014-01-20
US9161965B2 (en) 2015-10-20
EP2307035A2 (en) 2011-04-13
WO2009140416A2 (en) 2009-11-19
AU2009246316B2 (en) 2014-06-19
JP2016199553A (ja) 2016-12-01

Similar Documents

Publication Publication Date Title
ES2446306T3 (es) Uso de un inhibidor de psd-95 tratamiento para la epilepsia
ES2555172T3 (es) Péptidos inhibidores de receptores NMDA para uso en en tratamiento de trastornos de la ansiedad
ES2902467T3 (es) TIMP2 para su uso en el tratamiento de afecciones asociadas al envejecimiento
ES2273849T3 (es) Composiciones farmaceuticas que comprenden compuestos ciclicos peptidometicos con giro beta.
Wemmie et al. Acid-sensing ion channels in pain and disease
ES2804424T3 (es) Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
ES2847293T3 (es) Regímenes de tratamiento para el tratamiento de enfermedades neurológicas
ES2765281T3 (es) Coadministración de un agente unido a un péptido de interiorización con un agente antiinflamatorio
ES2397637T3 (es) Inhibidores de PAK para uso en el tratamiento de trastornos del desarrollo neurológico
ES2404940T3 (es) Reactivos de peptoide específicos para prión
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
KR20140038435A (ko) 허혈성 뇌 손상에 대한 효과적인 신경보호제이며 통증의 치료를 위한 ｐｓｄ-95의 고-친화성, 이량체 저해제
CN103282379B (zh) Nd2肽和神经疾病的治疗方法
ES2869300T3 (es) Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
US9139615B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
ES2745220T3 (es) Modulación del sistema receptor Trpv:receptor de dominio Vps10p para el tratamiento del dolor